1. Table of Contents
1.1 List of Figures
1.2 List of Tables

2. Executive Summary
2.1 Hormone-Sensitive Prostate Cancer Clinical Trials Overview, 2019
2.2 Premium Insights into Clinical Trials
2.2.1 Hormone-Sensitive Prostate Cancer Clinical Trials by Region
2.2.2 Average Enrollment of Hormone-Sensitive Prostate Cancer Clinical Trials
2.2.3 Companies participating in Trials
2.2.4 Drugs under Study for Hormone-Sensitive Prostate Cancer Treatment, 2019

3. Region wise Hormone-Sensitive Prostate Cancer Clinical Trials
3.1 Asia Pacific Hormone-Sensitive Prostate Cancer Clinical Trials by Country
3.2 Europe Hormone-Sensitive Prostate Cancer Clinical Trials by Country
3.3 North America Hormone-Sensitive Prostate Cancer Clinical Trials by Country
3.4 Middle East and Africa Hormone-Sensitive Prostate Cancer Clinical Trials by Country
3.5 South and Central America Hormone-Sensitive Prostate Cancer Clinical Trials by Country

4. Hormone-Sensitive Prostate Cancer Clinical Trial Trends
4.1 Start Year wise Hormone-Sensitive Prostate Cancer Clinical Trials
4.2 Phase wise Hormone-Sensitive Prostate Cancer Clinical Trials
4.3 Trial Status wise Hormone-Sensitive Prostate Cancer Clinical Trials
4.4 Trial Type wise Hormone-Sensitive Prostate Cancer Clinical Trials

5. Hormone-Sensitive Prostate Cancer Average Enrollment Trends
5.1 Average Enrollment in Hormone-Sensitive Prostate Cancer Trials by Year
5.2 Average Enrollment in Hormone-Sensitive Prostate Cancer Trials by Phase
5.3 Average Enrollment in Hormone-Sensitive Prostate Cancer Trials by Status
5.4 Average Enrollment in Hormone-Sensitive Prostate Cancer Trials by Type of Trial

6. Companies Participating in Hormone-Sensitive Prostate Cancer Clinical Trials
6.1 Hormone-Sensitive Prostate Cancer Trials by Sponsor Type
6.2 Hormone-Sensitive Prostate Cancer Average Enrollment by Sponsor Type
6.3 Subjects Recruited by Leading Sponsors

7 Trial Snapshots- Phase, Type, Title, Location, Start Year, Completion Year, Recruitment Status, Enrollment, Participating Countries, Trial Locations, Company, Drugs and Other Details
7.1 Hormone-Sensitive Prostate Cancer Trials- Phase 1
7.2 Hormone-Sensitive Prostate Cancer Trials- Phase 2
7.3 Hormone-Sensitive Prostate Cancer Trials- Phase 3
7.4 Hormone-Sensitive Prostate Cancer Trials- Phase 4

8. Appendix
8.1 Report Guidance
8.2 Research Methodology
8.3 Abbreviations
8.4 Definitions
8.5 Sources
8.6 Publisher Expertise

List of Figures
Figure 1: Hormone-Sensitive Prostate Cancer Clinical Trials by Region, 2019
Figure 2: Country wise Clinical Trials, 2019
Figure 3: Country wise Average Enrolment, 2019
Figure 4: Asia Pacific - Country wise Hormone-Sensitive Prostate Cancer Clinical Trials and Enrolment
Figure 5: Europe - Country wise Hormone-Sensitive Prostate Cancer Clinical Trials and Enrolment
Figure 6: Middle East Africa - Country wise Hormone-Sensitive Prostate Cancer Clinical Trials and Enrolment
Figure 7: North America - Country wise Hormone-Sensitive Prostate Cancer Clinical Trials and Enrolment
Figure 8: South and Central America - Country wise Hormone-Sensitive Prostate Cancer Clinical Trials and Enrolment
Figure 9: Hormone-Sensitive Prostate Cancer Clinical Trials by Phase
Figure 10: Hormone-Sensitive Prostate Cancer Clinical Trials by Trial Status
Figure 11: Hormone-Sensitive Prostate Cancer Clinical Trials by Type
Figure 12: Hormone-Sensitive Prostate Cancer Clinical Trials by Sponsor Type
Figure 13: Hormone-Sensitive Prostate Cancer Clinical Trials by Leading Sponsors
Figure 14: Hormone-Sensitive Prostate Cancer Average Enrollment by Phase
Figure 15: Hormone-Sensitive Prostate Cancer Average Enrollment by Trial Status
Figure 16: Hormone-Sensitive Prostate Cancer Average Enrollment by Type
Figure 17: Hormone-Sensitive Prostate Cancer- Average Enrolment by Type of Sponsors
Figure 18: Hormone-Sensitive Prostate Cancer- Enrolment by Leading Sponsors
Figure 19: VPAResearch- Research Methodology

List of Tables
Table 1: Hormone-Sensitive Prostate Cancer Clinical Trials Snapshot- 2019
Table 2: Trials by Region, 2019
Table 3: Country wise Clinical Trials and Average Enrolment by Country, 2019
Table 4: Asia Pacific - Country wise Hormone-Sensitive Prostate Cancer Clinical Trials and Enrolment
Table 5: Europe - Country wise Hormone-Sensitive Prostate Cancer Clinical Trials and Enrolment
Table 6: Middle East Africa - Country wise Hormone-Sensitive Prostate Cancer Clinical Trials and Enrolment
Table 7: North America - Country wise Hormone-Sensitive Prostate Cancer Clinical Trials and Enrolment
Table 8: South and Central America - Country wise Hormone-Sensitive Prostate Cancer Clinical Trials and Enrolment
Table 9: Clinical Trials by Phase
Table 10: Clinical Trials by Trial Status
Table 11: Clinical Trials by Type
Table 12: Clinical Trials by Sponsor Type
Table 13: Clinical Trials by Leading Sponsors
Table 14: Hormone-Sensitive Prostate Cancer Average Enrollment by Phase
Table 15: Hormone-Sensitive Prostate Cancer Average Enrollment by Trial Status
Table 16: Hormone-Sensitive Prostate Cancer Average Enrollment by Type
Table 17: Hormone-Sensitive Prostate Cancer- Average Enrolment by Type of Sponsors
Table 18: Hormone-Sensitive Prostate Cancer- Enrolment by Leading Sponsors

Companies mentioned
Ambrilia Biopharma Inc, Astellas Pharma Inc, Bayer AG, Besins Healthcare SA, Ferring Holding SA, Johnson & Johnson, Novartis AG, Orion Corporation, Pfizer Inc, Sanofi